文献速递性腺与生殖内分泌

24周与12周Decapeptyl SR治疗中枢性性早熟疗效比较:英国多中心回顾性队列研究

Efficacy of 24-weekly vs 12-weekly decapeptyl SR treatment in central precocious puberty: a UK multicentre retrospective cohort study.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

该英国多中心回顾性队列研究纳入164例中枢性性早熟患儿,比较每12周与每24周Decapeptyl SR治疗的疗效。两种方案均有效抑制下丘脑-垂体-性腺轴,在促性腺激素、性激素、身高增速、BMI及Tanner分期上无显著差异,24周方案耐受良好且所有表达偏好者均倾向24周方案。

要点

  • 24周Decapeptyl SR与12周方案在抑制HPG轴和青春期进展上等效。
  • 两种方案在LH、FSH、性激素、身高增速、BMI及Tanner分期上无显著差异。
  • 24周方案耐受良好,减少注射频率可能提高依从性和满意度。

核心结论

  • 24周Decapeptyl SR治疗中枢性性早熟有效且耐受良好,结局与标准12周方案相当。
  • 这是首个确立两种方案临床等效性的比较分析,考虑到长效制剂减少了临床监测频率,此结果尤为重要。

研究设计与样本

  • 多中心回顾性队列研究,纳入2008年9月至2024年12月在英国3家三级儿科内分泌中心接受GnRHa治疗的CPP患者。
  • 共回顾247例患者(220例女孩和27例男孩),164例纳入分析:组1(12周方案)69例,组2(24周方案)95例。
  • 患者接受Decapeptyl SR 11.25 mg每12周或22.5 mg每24周,收集基线和随访的临床、生化及影像学数据。

主要发现

  • 两种方案均实现有效的HPG轴抑制,促黄体生成素、促卵泡激素或性激素浓度无显著差异。
  • 身高增速、体重指数和Tanner分期等临床结局相当。
  • 24周制剂耐受良好,展示等效的青春期进展抑制。
  • 在表达偏好的患者中,全部倾向于24周方案。

临床怎么用

  • 24周Decapeptyl SR可作为中枢性性早熟的有效治疗选择,与12周方案疗效相当。
  • 减少注射频率可能改善依从性和患者满意度,并可能节省费用。
  • 长效制剂减少临床监测频率,但需注意研究中未报告监测频率的具体差异。

局限性

  • 回顾性队列设计可能存在选择偏倚和信息偏倚。
  • 研究未报告样本量计算、P值或置信区间等详细统计指标。
  • 偏好24周方案的患者比例及偏好数据收集方法未详细说明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy of 24-weekly decapeptyl SR (Triptorelin) treatment, compared with the 12-weekly regimen, in children with central precocious puberty (CPP). METHODS: A multicenter retrospective cohort study was conducted on patients with CPP treated with gonadotropin-releasing hormone analog (GnRHa) therapy between September 2008 and December 2024. Participants were recruited from 3 tertiary pediatric endocrinology centers in the United Kingdom: the Royal London Hospital (Barts Health NHS Trust), Sheffield Children's Hospital (Sheffield Children's NHS Foundation Trust), and the Royal Victoria Infirmary (Newcastle upon Tyne Hospitals NHS Foundation Trust). Patients received either Decapeptyl SR 11.25 mg every 12 weeks or 22.5 mg every 24 weeks. Clinical, biochemical, and radiological data were collected at baseline and follow-up to assess hypothalamic-pituitary-gonadal (HPG) axis suppression and pubertal progression. RESULTS: Of 247 patients reviewed (220 girls and 27 boys), 164 were eligible for analysis: 69 in Group 1 (12 weekly) and 95 in Group 2 (24 weekly). Both regimens achieved effective HPG axis suppression, with no significant differences in luteinizing hormone, follicle-stimulating hormone, or sex steroid concentrations. Clinical outcomes, including height velocity, body mass index, and Tanner staging, were comparable. The 24-weekly preparation was well-tolerated and demonstrated equivalent suppression of pubertal progression. Among patients who expressed a preference, all favored the 24-weekly schedule. CONCLUSION: This UK multicenter study provides evidence that 24-weekly Decapeptyl SR is both efficacious and well-tolerated for the management of CPP, with comparable outcomes to the standard 12-weekly regimen. This is the first comparative analysis to establish clinical equivalence between these 2 regimens, which is particularly important given the reduced frequency of clinical monitoring in the longer-acting preparation. Fewer injections may improve adherence and patient satisfaction, alongside potential cost savings.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Varughese R, Lake L, Kothayan B, et al. Efficacy of 24-weekly vs 12-weekly decapeptyl SR treatment in central precocious puberty: a UK multicentre retrospective cohort study. J Clin Endocrinol Metab. 2026. PMID: 41793064. doi:10.1210/clinem/dgag096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。